Accessibility Menu
Eloxx Pharmaceuticals logo

Eloxx Pharmaceuticals(NASDAQ) ELOX

Market Cap$513.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-98%
1 Year+1,112,627%
1 Month+3%
$12.60
-1.68%
-0.21Today
Eloxx Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 12.242026-07-29
Eloxx Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.84%USD 12.472026-07-22
1 month+2.6%USD 11.932026-06-29
3 month+518.18%USD 1.982026-04-30
Year to date+1,112,627.27%USD 0.002025-12-31
1 year+1,112,627.27%USD 0.002025-07-29
3 year-82.31%USD 69.192023-07-28
5 year-97.89%USD 580.802021-07-30
Since inception-99.65%USD 3,625.602017-12-21

Eloxx Pharmaceuticals Financials at a Glance

Market Cap

$513.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$13.40M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-16692.69 (Low)

Price

$12.60

Volume

1

Open

$13.36

Previous Close

$12.24

Daily Range

$12.01 - $14.00

52-Week Range

$12.01 - $17.50

Estimated Earnings Date

Aug 10, 2026

ELOX News

AMD Radeon

Why Advanced Micro Devices, Ciena, and Eloxx Pharmaceuticals Jumped Today

Dan CaplingerJun 6, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eloxx Pharmaceuticals

Eloxx develops medicines for rare genetic diseases with no current cures. Its main drugs aim to help people with inherited kidney and skin disorders. These treatments target the root cause of disease by restoring missing proteins.

Products and Services

  • Exaluren (Lead Drug): Investigational therapy for rare kidney diseases caused by genetic mutations; 0% of 2025 revenue.
  • ZKN-013 (Pipeline Drug): Oral treatment for rare skin diseases, developed with Almirall; 100% of 2024 revenue.
  • Preclinical Programs: Early-stage research for cancer and other rare inherited diseases; 0% of revenue.
  • Licensing Agreements: Revenue from partnerships, not product sales; 100% of 2024 revenue.

Growth and Expansion

  • Signed exclusive global rights deal with Almirall for ZKN-013 in March 2024.
  • Received $6 million in upfront and milestone payments from Almirall in 2024.
  • Raised $15 million from Coastlands Capital Partners and $2 million from Domicilium in 2025.
  • Reduced workforce and restructured debt in 2025 to manage liquidity.
  • Delisted from Nasdaq in October 2023; now trades on OTC Expert Market.

What Makes Eloxx Stand Out

Eloxx focuses on ribosome modulation, a method that targets the genetic root of rare diseases. Its drugs are designed to restore missing proteins in patients with specific mutations. The company relies on strategic partnerships and patent protection to advance its pipeline.

Five Things You Need to Know

  • Revenue was $0 in 2025, down 100% from $6.4 million in 2024.
  • All 2024 revenue came from a single licensing deal with Almirall.
  • Operating loss was $6.4 million in 2025, down 63% from 2023.
  • Cash and equivalents were $4.8 million at December 31, 2025.
  • Accumulated deficit reached $300.6 million by end of 2025.

Bottom Line

Eloxx has shifted from product development to partnership-driven funding and cost control. The company’s future depends on new clinical results and additional financing.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10

CEO

Sumit Aggarwal, MBA

Website

www.eloxxpharma.com

Headquarters

Watertown, MA 02472, US

ELOX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

72.03%

Return on Capital

N/A

Return on Assets

-64.25%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$513.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

41.90K

Volume

1

Avg. Volume

42.74K

Financials (TTM)

Gross Profit

-$373.00K

Operating Income

-$12.79M

EBITDA

-$12.05M

Operating Cash Flow

-$9.76M

Capital Expenditure

$0.00

Free Cash Flow

-$9.76M

Cash & ST Invst.

$6.36M

Total Debt

$0.00

Eloxx Pharmaceuticals Performance Analysis

Eloxx Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20252025-12-31USD 0N/A
Eloxx Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-30N/A
Q32023-09-30N/A
Q12025-03-31N/A
Q12026-03-31N/A
Eloxx Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -419.65N/A
20222022-12-31USD -183.13-56.4%
20252025-12-31USD -5.34-97.1%
Eloxx Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-3031.9%
Q32023-09-3033.2%
Q12025-03-31N/A
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$513.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$51.33K

N/A

Employees

10

N/A

Net Income

-$3.75M

+39.7%

EBITDA

-$3.73M

+33.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.36M

-67.3%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-64.25%

N/A

Return on Invested Capital

66.15%

N/A

Free Cash Flow

-$5.45M

+20.0%

Operating Cash Flow

-$5.45M

+20.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NMSCANutrition Management Services Company
$0.00+0.00%
NBRVFNabriva Therapeutics plc
$0.00+0.00%
OMDDOrmand Industries Inc
$0.00+0.00%
BIOCQBiocept, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About ELOX

What is the current price of Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals is trading at $12.24 per share.

What is the 52-week range for Eloxx Pharmaceuticals?

Over the past 52 weeks, Eloxx Pharmaceuticals has traded between $12.01 and $17.50.

How much debt does Eloxx Pharmaceuticals have?

As of the most recent reporting period, Eloxx Pharmaceuticals reported total debt of $0.00.

How much cash does Eloxx Pharmaceuticals have on hand?

Eloxx Pharmaceuticals reported $6.37M in cash and cash equivalents in its most recent financial results.

What is Eloxx Pharmaceuticals’s dividend yield?

Eloxx Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services